To confirm the inhibitory role of Notch1-WISP-1 signaling in CAF activation and tumor progression in vivo, the Notch1-selective inhibitor LY3039478 (8 mg/kg) was administered orally three times a week for 6 weeks beginning the day before injection of ApoSQ (Fig. 7a). This evidence concerns the gene NOTCH1 and neoplasm.